Salarius Pharmaceuticals advanced dose escalation in Ewing Sarcoma trial with early stage clinical readouts in 2020. The company reached the sixth level dosing cohort in its phase 1/2 study of Seclidemstat in Ewing sarcoma upon the Safety Committee Review. Seclidemstat has re...

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, announced today that its chief executive officer, David Arthur, will present at the Noble Capital Markets’ 16th Annual Small & Micro...

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, announced today that its chief executive officer, David Arthur, will present at the BIO CEO & Investor Conference being held Februar...